Xinyun Tang
Yuxin Huang1,2†
Xuliang Fang
Fangda Fu- 1Institute of Orthopaedics and Traumatology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Traditional Chinese Medicine), Hangzhou, China
- 2The First Clinical Medical College, Zhejiang Chinese Medical University, Zhejiang, China
- 3The Third Clinical Medical College, Zhejiang Chinese Medical University, Zhejiang, China
- 4Department of Orthopedics, Taizhou Municipal Hospital, Taizhou, China
Osteoporosis (OP) is a systemic metabolic skeletal disorder characterized by a decline in bone mass, bone mineral density, and deterioration of bone microstructure. It is prevalent among the elderly, particularly postmenopausal women, and poses a substantial burden to patients and society due to the high incidence of fragility fractures. Kidney-tonifying Traditional Chinese medicine (TCM) has long been utilized for OP prevention and treatment. In contrast to conventional approaches such as hormone replacement therapy, TCM offers distinct advantages such as minimal side effects, low toxicity, excellent tolerability, and suitability for long-term administration. Extensive experimental evidence supports the efficacy of kidney-tonifying TCM, exemplified by formulations based on the renowned herb Cornus officinalis and its bioactive constituents, including morroniside, sweroside, flavonol kaempferol, Cornuside I, in OP treatment. In this review, we provide a comprehensive elucidation of the underlying pathological principles governing OP, with particular emphasis on bone marrow mesenchymal stem cells, the homeostasis of osteogenic and osteoclastic, and the regulation of vascular and immune systems, all of which critically influence bone homeostasis. Furthermore, the therapeutic mechanisms of Cornus officinalis-based TCM formulations and Cornus officinalis-derived active constituents are discussed. In conclusion, this review aims to enhance understanding of the pharmacological mechanisms responsible for the anti-OP effects of kidney-tonifying TCM, specifically focusing on Cornus officinalis, and seeks to explore more efficacious and safer treatment strategies for OP.
Introduction
Osteoporosis (OP), a global skeletal disorder often referred to as the “silent disease,” is characterized by bone mass loss and microstructure degeneration, leading to an increase in the risk of fractures and imposing a substantial socioeconomic burden (1, 2). It is estimated that the number of fractures causing by OP will reach 2.6 million in 2025, double the total number in 1990, and will reach 4.5 million by 2050 in the world (3). Moreover, increasing evidence indicates that women and older individuals are particularly vulnerable to OP and its consequences, with 1/3 of women and 1/5 of men aged 50 and above experiencing osteoporotic fractures globally (1). However, prolonged use of anti-OP medication such as denosumab, teriparatide, bisphosphonates, calcitonin, and estrogen, can result in undesirable side effects, including an increased risk of malignancy, atypical femur fractures, osteonecrosis of the jaw, and cardiovascular issues (4). The concern over these side effects and the uncertain long-term efficacy of pharmacological treatments has prompted the search for alternative medications with fewer adverse events, low toxicity, high efficacy, and good tolerability.
An increasing number of researchers are exploring Traditional Chinese Medicine (TCM) as an alternative treatment for OP due to its fewer adverse events and long-term safety profile (5). Cornus officinalis (known as Shanzhuyu in Chinese), an ingredient commonly found in TCM formulas for bone-related diseases such as Zuo Gui Pill (ZGP) (6, 7), You Gui Pill (YGP) (7), and Liuwei Dihuang Pill (LWDHP) (8), all of which are known for its kidney-nourishing properties, exerts beneficial effects in the prevention and treatment of OP by alleviating common symptoms experienced by individuals with OP such as lumbar and knee discomfort (9, 10). Furthermore, recent research has highlighted the therapeutic potential of certain monomeric components derived from Cornus officinalis, independent of its inclusion in TCM formulations including flavonoids, tannins, iridoids, organic acids, polysaccharides, and lignans (11). Among them, gallic acid, morroniside, loganin, sweroside, quercetin, notoginsenoside R1, cornuside I, kaempferol, and 5-HMF, extracted from Cornus officinalis, may play a crucial role in OP treatment (12).
In this review, we comprehensively summarize the research on Cornus officinalis in the context of OP, focusing primarily on its mechanisms of action involving bone homeostasis, immunomodulation, vascularity, and bone microarchitecture, thus providing a better understanding of the therapeutic role played by Cornus officinalis in the pathological process of OP and its potential clinical application.
Pathomechanism of OP
OP is a common metabolic bone disease associated with a variety of factors such as bone homeostasis, immune mechanisms, vascular changes, estrogen deficiency, mechanical stress, and the nervous system. In this section, we will discuss the pathological of OP related to these factors.
Bone homeostasis
Several key cells in bone tissue, such as bone mesenchymal stem cells (BMSC), osteoblast (OB), and osteoclast (OC), play critical roles in bone remodeling, including bone formation and bone resorption (13). Particularly, BMSC can mainly differentiate into adipocytes and OB in bone, to play an important role in the regulation of normal bone homeostasis (14). The capacity of BMSC from OP patients to differentiate into OB is lower than that in healthy individuals (14). The shift in preferential differentiation of MSCs from OB to adipocytes accompanied by reduced bone mineral density (BMD) can contribute to OP progression (15). OB secrete various components of osteoid, such as collagen I, alkaline phosphatase (ALP), osteopontin (OPN), and osteocalcin (OCN), which then mineralize to form mature bone (16, 17). Additionally, precursor OC are enlisted and attached to the bone matrix, subsequently undergoing further differentiation into mature OC, which can release acids and lytic enzymes that facilitate the degradation of the bone matrix and absorption of aging and damaged bone tissue (18, 19). As evidenced by disturbed bone homeostasis, altered bone microstructure, and reduced bone strength, OP arises from the imbalance of bone formation and bone resorption, resulting from excessive absorption by OC or impaired generation of OB (17, 20).
Moreover, various regulatory factors and signaling pathways impact the activity of BMSC, OB, and OC, thus governing the process of bone resorption and formation processes. Significant roles are played by signaling pathways such as Wnt/β-catenin, bone morphogenetic proteins (BMP)-Smad, Hedgehog, receptor activator of nuclear factor-B ligand (RANKL)/receptor activator of nuclear factor-B (RANK)/osteoprotegerin (OPG), along with several regulatory factors. Notably, the canonical Wnt/β-catenin signaling pathway has emerged as a crucial regulator of bone formation, promoting the osteogenic process, preventing apoptosis of OB precursors, facilitating OB differentiation and inhibiting BMSC differentiation into adipocytes (21, 22). Conversely, inhibiting Wnt pathway impedes bone formation, rendering individuals more susceptible to early-onset OP and osteogenesis imperfecta (13). Similarly, activation of Hedgehog signaling pathway promotes the differentiation of BMSC into OB rather than adipocytes by upregulating Runx-2 expression, thereby enhancing bone formation (23, 24). Moreover, specific BMP and canonical TGF-β positively regulate osteogenic activity by phosphorylating downstream Smad proteins, thereby influencing the balance between OB-mediated bone formation and OC-mediated bone resorption (23, 25, 26).
Furthermore, the RANKL/RANK/OPG signaling pathway represents the most extensively studied pathway concerning OC differentiation and activity. OB release RANKL, which binds to RANK, a specific receptor on the surface of OC, triggering the transcription of downstream factors, such as c-FOS, NFATc1, tartrate-resistant acid phosphatase (TRAP), and cathepsin K (CTSK), ultimately leading to the differentiation and activation of OC (27). Meanwhile, OPG, which is also secreted by OB, competitively binds to RANK, suppressing OC activity and safeguarding bones against excessive resorption (28, 29).
The role of Notch signaling pathway in bone remodeling relies on the type of Notch receptor involved: Notch 1 fosters increased OPG production and decreased sclerostin, exerting osteoprotective effects by inhibiting OC formation and bone resorption, while Notch2 promotes osteoclastogenesis and enhances bone resorption by stimulating RANKL expression (30). In summary, OP arises from an imbalance between bone formation and bone resorption within bone homeostasis, stemming from the dysregulation of multiple signaling pathways.
In summary, BMSC and OB play roles in bone formation, while OC affect bone resorption. Together, they mediate OP through different factors (Figure 1).
Figure 1. Schematic working model of OP. In a normal physiological state of healthy bone, BMSC can differentiate into OB, and OB further mature into osteocytes. Meanwhile, OB secretes Collagen I, ALP, OPN, Osteonectin, and other substances to constitute bone matrix. Under pathological state, the upregulation of Notch 2/RANKU/RANK/OPG signaling pathway promoting OC generation and the downregulation of Wnt/β-catenin/TGF-B/BMP-Smad/Hedgehog signaling pathway inhibiting osteogenesis, ultimately lead to OP.
Vasculature
The vascular system in bones contributes to the supply of oxygen, nutrients, hormones, growth factors, and neurotransmitters necessary for the normal growth, development, regeneration, and remodeling of bone. Emerging evidence reveals that the metabolic imbalance in the bone microenvironment caused by blood vessel supply impairment, along with the imbalance of vascular calcium, phosphorus and glucose metabolism, is intricately associated with the pathological mechanisms of OP (31). For instance, adjustment of the number and size of blood vessels along the flow has confirmed that the skeletal system occupies 10 and 15% of the total cardiac output, which is crucial for skeletal system health. And insufficient blood flow can lead to delayed bone repair and other low bone mass diseases due to impaired osteogenesis (32, 33). Moreover, a female patient with a rare Hajdu-Cheney syndrome causing periarticular OP showed reduced the height and density of blood vessels in all affected fingers (34). Triggering the activation of the HIF signaling pathway in OB could prevent the reduction of blood vessels in the bone marrow of postmenopausal OP patients to prevent bone loss (35). Another study showed that supplementation of ribonuclease-rich lactoferrin promotes new vessels formation, achieving a significant reduction in bone resorption and an increase in bone formation to restore bone homeostasis (36).
Blood vessels inside bones are generally identified two types: The type H vessels with high expression of CD31 and endomucin mainly localized in the vicinity of the chondro–osseous junction, and the type L vessels with low expression of CD31 and endomucin mainly localized in the diaphysis (37). The number of Type L vessels, which does not change over time, are basically not involved in bone metabolism (37). Contrary to type L vessels, type H vessels maintain OB around blood vessels, which has been proved to be an important carrier of to induce angiogenesis and bone formation (38–40). Researches indicate a corresponding reduction in the number of type H blood vessels in aged OP mice, ovariectomized (OVX) induced OP mice, as well as in elderly and OP patients, accompanied by loss of bone precursor cells (37–40). In turn, promoting the maturation of Type H vessels by activating Notch signaling can regulate the differentiation of perivascular osteoprogenitor cells and accelerate osteogenesis (41).
The levels of calcium, phosphorus, and glucose in blood vessels, as well as their metabolic balance, are also closely related to OP. Studies have observed significant decreases in BMD, osteoclastic strength, serum ALP, and calcium and phosphorus in the OP model after ovariectomy (42–46). In addition, abnormal calcium loss of bone tissue, accompanied by calcium deposits within blood vessels causing vascular calcification, contributes to the pathogenesis of OP, known as the “calcium paradox” (47, 48). The aggravation of vascular calcium deposition obstructs nutrient supply to bone tissue and further promotes the pathogenesis of OP. On the other hand, output venous vessels in Haversian and Volkmann ducts allow immune cells to migrate from the basement membrane to the deeper layers of dense bone, becoming a site for mineral reabsorption during OP (49). Furthermore, abnormal blood glucose levels downregulate PI3K-AKT signaling pathway to inhibit OB activity and promote OC activity in the trabecular bone region with reduced serum level of OCN and ALP (50, 51). All these findings underscore the close relationship between blood vessels and the pathological process of OP, particularly the number of type H vessels and capillaries, bone blood flow and vascular calcium deposition besides vascular calcium, phosphorus and glucose metabolism (31, 34–36, 48, 49).
In conclusion, activating neovascularization, promoting bone blood flow, and balancing calcium level between blood vessels and bone tissue are therapeutic strategies for OP management.
Immune system
Osteoimmunology is an interdisciplinary field arising from mounting evidence of the close relationship between the immune system and bone metabolism (52–54). Relevant studies have shown that many immune cells in the bone system, including T lymphocytes, B lymphocytes and macrophages, affect bone cells in the bone system directly or indirectly through the secretion of mediators by immune cells such as OPG/RANKL, COX-2, interleukins, and tumor necrosis factor (TNF) (52, 54–64).
Th2 lymphocytes, through the release of IL-4 and IL-13, act to prevent the formation of OC by downregulating prostaglandin dependent on COX-2, thereby suppressing bone resorption (54, 56). Conversely, Th17 lymphocytes, as the main source of IL-17, promote osteoclastic differentiation in vitro and the generation of RANKL, resulting in bone loss in mice with primary hyperparathyroidism (57–59). Meanwhile, IL-17 also promotes the early differentiation of OB by increasing the expression of ALP, RUNX2, OCN, and OPG (61–63). Besides, the upregulation of TNF-α expression in T-lymphocytes, under the regulation of RANKL, promotes the apoptosis of OB (60, 64).
The B lymphocytes, on the other hand, reduce OB differentiation by acting through CCL3 and TNF, which target ERK and NF-κB signaling pathways (65). In addition, B lymphocytes secrete various cytokines that play a dual role in OC: On one hand, they produce IL-7 (66), RANK (67), and approximately half of the total OPG (68) in the bone marrow, suppressing OC activation; On the other hand, B lymphocytes secrete G-CSF and RANKL under inflammatory conditions, promoting the differentiation and proliferation of OC, thus leading to bone resorption (69). Surprisingly, IL-18, initially considered an up-regulator of OPG that inhibits osteoclastogenesis, was subsequently found to increase the expression of RANKL on T lymphocytes, ultimately promoting bone mass loss (70).
Macrophages presented in bones are known as various populations: bone marrow macrophages (BMMs), OC, and osteal macrophages (71), all of which can categorized into two phenotypes—M1 (inflammatory phenotype) and M2 (reparative phenotype)—playing different roles in bone homeostasis. M1 macrophages, considered as precursors of OC (72), polarize after stimulation by pro-inflammatory cytokines IL-6, TNF-α, and IFN-γ (73), triggering osteoclastogenesis and subsequent bone destruction (74). Interestingly, RANKL-induced M1 macrophages contribute to the expression of OPN and RUNX2 in BMSC, inducing osteogenesis as a contrary effect (75). Conversely, M2 macrophages polarize under stimulation by anti-inflammatory cytokines such as IL-4 and IL-13, and stimulate MSCs or pre-osteoblastic cells to differentiate into OB, promoting bone formation. Moreover, increased transition from M1 to M2 macrophages enhances this trend (53, 73, 76). Hence, regulating the ratio of M1/M2 macrophages holds the potential therapeutic effect of anti-OP.
Other factors
Many other factors, including nervous system, mechanical stress, estrogen, and oxidative stress, contributing to OP based on available data. To maintain proper bone balance, the nervous system enters mature bones, regulates blood flow and metabolism, and secretes neurotransmitters (77). Neuropeptide-Y (NPY), a classic neuronal regulator of energy homeostasis, directly inhibits BMSC proliferation and OB differentiation through the Y1 receptor on the surface of BMSC or OB and the Y2 receptor in hypothalamus, thereby suppressing bone formation and leading to OP (78–81). Moreover, mechanical stress also impacts OP, preventing osteoporotic bone loss through the Pl3k/Akt signaling and erythropoiesis (82). Estrogen, in order to protect the bones, inhibits OB apoptosis and OC formation by reducing the expression of RANKL, which also promotes the apoptosis of OC (83), which contributes to an increase in the incidence of OP among postmenopausal women. Furthermore, increased oxidative stress raises TNF-α levels in serum while reducing Sirtuin 6 (Sirt6) expression in long bones, promoting NF-κB acetylation as well as CTSK over-expression and activation (84), consequently leading to bone destruction (85, 86).
Anti-OP effects of Cornus officinalis and effective ingredients or Chinese formulations
BMSC and OB are the therapeutic targets of Cornus officinalis and its active ingredients or compounds to exert an anti-OP role
Cornus officinalis has been traditionally employed in East Asia for the treatment of OP. This botanical resource boasts abundant active ingredients that exert diverse effects on OP by modulating the proliferation and differentiation capacity of BMSC, promoting osteogenic differentiation, and ameliorating the OP phenotype.
The aforementioned findings, presented in Table 1, support the notion that promoting BMSC proliferation and osteogenic differentiation, inhibiting lipogenic differentiation, enhancing osteogenesis related protein such as BMP2, Osx, RUNX2, ALP, OPN, OCN by regulating Wnt/β-catenin, BMP, PI3K/AKT/mTOR, AMPK, JNK, ERK, NF-κB signaling pathways represent promising therapeutic strategies for the treatment of OP mediated by the efficacious components of Cornus officinalis.
Table 1. Active ingredients of Cornus officinalis for BMSC and OB.
OC is another therapeutic targets of Cornus officinalis and its active ingredients or compounds to exert an anti-OP role
OC is bone-resorbing cell that degrades bone through acid secretion and the release of proteolytic enzymes (107). Cornus officinalis processes the ability to restrict the differentiation of bone marrow-derived macrophages (BMMs) into OC, and suppress the translation and genetic transcription of OC-associated markers. These anti-OP effects are achieved via the active ingredients of Cornus officinalis (Table 2) (119).
Table 2. Active ingredients of Cornus officinalis for OC.
In conclusion, Cornus officinalis and its active constituents modulate the function, activity, and quantity of OC by inhibiting MAPK, AKT, ERK, JNK signaling pathways to reduce the expression of OC-related proteins RANKL, c-Fos, NFATc1 and CTSK, thus inhibit bone resorption. These novel findings designate Cornus officinalis and its active constituents as potential therapeutic anti-OC targets for the treatment of OP.
The vascular system is one of the therapeutic targets of Cornus officinalis and its active ingredients or compounds exert an anti-OP role
Angiogenesis, nutritional support function, and the metabolism of blood calcium, phosphorus, and glucose are directly related to bone development and regeneration. In the context of bone diseases, vascular function is often impaired, accompanied by metabolic imbalances (42–46, 50, 51). An increasing body of evidence demonstrates the significant role of Cornus officinalis, its compounds, and active ingredients in addressing this issue. The following Table 3 elaborates a detailed account of their respective targets in the prevention of OP.
Table 3. Active ingredients of Cornus officinalis targeting vasculature system.
These findings suggest that Cornus officinalis and its active component and compounds hold potential as a therapeutic option for OP prevention by promoting angiogenesis, enhancing bone blood flow through regulation of HIF-1α, CD31, VEGF and its receptors, and balancing calcium, phosphorus and glucose metabolism between blood vessels and bone tissues (122). Based on the aforementioned experimental data, Cornus officinalis, in conjunction with its formula and monomer compounds, offers potential advantages in improving blood vessels in bones and thus playing a role in the management of OP.
The immune system is one of the therapeutic target of Cornus officinalis and its active ingredients or compounds exert an anti-OP role
It has been found that several kinds of immune cells can interact with OB and OC to combat OP (52). As mentioned above (the immune system part), immune cells in bone system, including T lymphocytes, B lymphocytes and macrophage, can participate in the regulation of differentiation into OB or OC by the secretion of inflammatory factors such as interleukins and TNF. Therefore, improving the inflammatory microenvironment may have the potential to regulate the function of immune cells, promote BMSC differentiation into OB and inhibit the mature of OC precursor. Previous research has indicated that active ingredients in Cornus officinalis, such as 5-HMF, Cornuside, loganin, and sweroside, possess anti-inflammatory properties, however, it remains uncertain whether these substances also serve as preventatives for OP (123–126). In this context, a recent study has discovered that kaempferol may suppress the upregulation of proinflammatory cytokines induced by LPS in BMSC, promote the production of anti-inflammatory factors, and inhibit the process of osteoclastogenesis and bone resorption induced by proinflammatory factor IL-1β (94). Other studies also showed that quercetin, loganin or morroniside could enhanced the M2 macrophage polarization by targeting NF-κB and Nrf2 signaling pathways indicating potential ability to promote osteoblastic differentiation and inhibit osteoclastic differentiation (127–129). Consequently, we conclude that Cornus officinalis and its active ingredients represent a potential therapeutic class with anti-inflammatory properties that can inhibit the progression of OP.
Other factors are the other therapeutic targets of Cornus officinalis and its active ingredients or compounds to exert an anti-OP role
Oxidative stress and estrogen play important roles in maintaining bone balance, and abnormal expression of these factors leads to OP (83–86). Numerous reports have confirmed the significant effects of the active ingredients and compounds in Cornus officinalis for the treatment of OP. Table 4 elaborates on their respective targets in treating OP.
Table 4. The active ingredients of Cornus officinalis for other factors.
These results suggest that Cornus officinalis, along with its active components, can inhibit OB apoptosis and OC formation by suppressing oxidative stress response and binding estrogen receptors, which aids in promoting OB differentiation. Based on the above findings, both Cornus officinalis and its active components offer potential advantages in maintaining bone balance and thus taking an important part in the treatment and prevention of OP.
An anti-OP effect exerted by Cornus officinalis-containing formulations
Cornus officinalis is a constituent of many TCM formulations such as ZGP, YGP, LWDHP, Bu-Shen-Tong-Luo decoction (BSTLD), all of which are known for their kidney-nourishing properties, and extensive evidence supports the favorable impact of these formulations in the prevention and treatment of OP (Table 5) (33, 51, 134–138).
Table 5. The Cornus officinalis-containing formulations for anti-OP effect.
These results suggest that Cornus officinalis-containing formulations could mainly improve BMD and bone microstructure, stimulate osteogenetic process, increases blood perfusion in bone marrow by reversing the Th17/Treg ratio or targeting PI3K-AKT and Wnt/β-catenin signaling pathway. Based on the above findings, Cornus officinalis-containing formulations offer potential advantage in promoting osteogenesis in the treatment and prevention of OP.
Conclusion and perspectives
OP is a skeletal condition characterized by reduced BMD and compromised trabecular bone structure, which significantly increases the likelihood of fractures and imposes substantial physical and financial burdens. Within TCM application, Cornus officinalis is widely employed for OP treatment. Both preclinical and clinical investigations have demonstrated the effectiveness of the chemical constituents and associated formulations of Cornus officinalis in preventing OP, which efficacy is attributed to various mechanisms, including the modulation of bone homeostasis, promotion of angiogenesis, anti-inflammatory effects, and regulation of the immune system, etc (Figure 2). Therefore, phytochemicals from Cornus officinalis possess significant potential for the development of novel anti-osteoporotic medications. Herein, we provide a comprehensive review of the role of Cornus officinalis in multiple anti-OP mechanisms, which aligns with the multifactorial nature of OP’s etiology and surpasses the traditional model of single drug targeting single aspects of medicine. By thoroughly investigating the therapeutic properties of Cornus officinalis in the context of OP treatment, our aim is to enhance our understanding of TCM’s underlying mechanisms in addressing this condition. This endeavor is expected to greatly contribute to the advancement of more efficacious pharmaceutical interventions for OP. Thus, systematic data mining of the existing Cornus officinalis database can undoubtedly aid in the drug discovery process by identifying safe candidates.
Figure 2. The protective mechanism involved in Cornus officinalis against OP in BMSC, OB and OC, immune system, vasculature, and other factors.
While several compounds, such as quercetin and kaempferol, extracted from Cornus officinalis, have been extensively studied in relation to OP, further investigation is necessary to explore the potential effects of sweroside, notoginsenoside R1, cornuside I, morroniside, and loganin. Additionally, it is essential to identify the active components of Cornus officinalis through comprehensive investigations. Moreover, limitations exist in the current use of animal models for OP research. The majority of in vivo studies employ rodent models, which possess dissimilar cortical-to-cancellous bone ratios compared to humans, and inter-species cellular differences result in deficiencies in both in vivo and in vitro experiments, which must be further corroborated using in mammalian or primate models (139, 140). Furthermore, the existing research primarily focuses on the efficacy of Cornus officinalis in preclinical experiments, necessitating the need for clinical trials to substantiate its effectiveness and safety.
Author contributions
XTa: Writing – original draft. YH: Writing – original draft. XF: Writing – original draft. XTo: Writing – original draft. QY: Writing – original draft. WZ: Writing – review & editing. FF: Writing – review & editing.
Funding
The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was financially supported by the National Natural Science Foundation of China (nos.: 82174140, 82174401, 82104164, and 81973870), Natural Science Foundation of Zhejiang Province (nos.: LQ23H270003, LY22H270003, and LQ19H080001), Joint Funds of the Zhejiang Provincial Natural Science Foundation of China (no. LBY22H270008), Traditional Chinese Medical Administration of Zhejiang Province (nos.: 2023ZR019, 2023ZL128, 2022ZX005, 2022ZB119, 2021ZB090, and 2018ZB136), Zhejiang medical and health science and technology project (nos.: 2023RC194 and 2021KY222), and Research Project of Zhejiang Chinese Medical University (nos.: 2021JKZDZC02 and 2021JKZKTS036A).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1. Johnston, CB, and Dagar, M. Osteoporosis in older adults. Med Clin North Am. (2020) 104:873–84. doi: 10.1016/j.mcna.2020.06.004
2. Kurra, S, Fink, DA, and Siris, ES. Osteoporosis-associated fracture and diabetes. Endocrinol Metab Clin N Am. (2014) 43:233–43. doi: 10.1016/j.ecl.2013.09.004
3. Gullberg, B, Johnell, O, and Kanis, JA. World-wide projections for hip fracture. Osteoporos Int. (1997) 7:407–13. doi: 10.1007/PL00004148
4. Compston, JE, McClung, MR, and Leslie, WD. Osteoporosis. Lancet. (2019) 393:364–76. doi: 10.1016/S0140-6736(18)32112-3
5. He, J, Li, X, Wang, Z, Bennett, S, Chen, K, Xiao, Z, et al. Therapeutic anabolic and Anticatabolic benefits of natural Chinese medicines for the treatment of osteoporosis. Front Pharmacol. (2019) 10:1344. doi: 10.3389/fphar.2019.01344
6. Li, J, Sun, K, Qi, B, Feng, G, Wang, W, Sun, Q, et al. An evaluation of the effects and safety of Zuogui pill for treating osteoporosis: current evidence for an ancient Chinese herbal formula. Phytother Res. (2021) 35:1754–67. doi: 10.1002/ptr.6908
7. Li, W, Liu, Z, Liu, L, Yang, F, Li, W, Zhang, K, et al. Effect of Zuogui pill and Yougui pill on osteoporosis: a randomized controlled trial. J Tradit Chin Med. (2018) 38:33–42. doi: 10.1016/j.jtcm.2018.01.005
8. Liu, Y, Wang, P, Shi, X, Li, H, Zhang, X, Zeng, S, et al. Liuwei Dihuang decoction for primary osteoporosis: a protocol for a systematic review and meta-analysis. Medicine. (2019) 98:e15282. doi: 10.1097/MD.0000000000015282
9. Wang, SJ, Yue, W, Rahman, K, Xin, HL, Zhang, QY, Qin, LP, et al. Mechanism of treatment of kidney deficiency and osteoporosis is similar by traditional Chinese medicine. Curr Pharm Des. (2016) 22:312–20. doi: 10.2174/1381612822666151112150346
10. Gao, X, Liu, Y, An, Z, and Ni, J. Active components and pharmacological effects of Cornus officinalis: literature review. Front Pharmacol. (2021) 12:633447. doi: 10.3389/fphar.2021.633447
11. Tenuta, MC, Deguin, B, Loizzo, MR, Cuyamendous, C, Bonesi, M, Sicari, V, et al. An overview of traditional uses, phytochemical compositions and biological activities of edible fruits of European and Asian Cornus species. Foods. (2022) 11:1240. doi: 10.3390/foods11091240
12. Ma, W, Wang, KJ, Cheng, CS, Yan, GQ, Lu, WL, Ge, JF, et al. Bioactive compounds from Cornus officinalis fruits and their effects on diabetic nephropathy. J Ethnopharmacol. (2014) 153:840–5. doi: 10.1016/j.jep.2014.03.051
13. Karner, CM, and Long, F. Wnt signaling and cellular metabolism in osteoblasts. Cell Mol Life Sci. (2017) 74:1649–57. doi: 10.1007/s00018-016-2425-5
14. Wang, C, Meng, H, Wang, X, Zhao, C, Peng, J, and Wang, Y. Differentiation of bone marrow mesenchymal stem cells in osteoblasts and adipocytes and its role in treatment of osteoporosis. Med Sci Monit. (2016) 22:226–33. doi: 10.12659/MSM.897044
15. Hu, L, Yin, C, Zhao, F, Ali, A, Ma, J, and Qian, A. Mesenchymal stem cells: cell fate decision to osteoblast or adipocyte and application in osteoporosis treatment. Int J Mol Sci. (2018) 19:360. doi: 10.3390/ijms19020360
16. Donsante, S, Palmisano, B, Serafini, M, Robey, PG, Corsi, A, and Riminucci, M. From stem cells to bone-forming cells. Int J Mol Sci. (2021) 22:989. doi: 10.3390/ijms22083989
17. Feng, X, and McDonald, JM. Disorders of bone remodeling. Annu Rev Pathol. (2011) 6:121–45. doi: 10.1146/annurev-pathol-011110-130203
18. Boyle, WJ, Simonet, WS, and Lacey, DL. Osteoclast differentiation and activation. Nature. (2003) 423:337–42. doi: 10.1038/nature01658
19. Siddiqui, JA, and Partridge, NC. Physiological bone remodeling: systemic regulation and growth factor involvement. Physiology. (2016) 31:233–45. doi: 10.1152/physiol.00061.2014
20. Eriksen, EF. Cellular mechanisms of bone remodeling. Rev Endocr Metab Disord. (2010) 11:219–27. doi: 10.1007/s11154-010-9153-1
21. Maeda, K, Kobayashi, Y, Koide, M, Uehara, S, Okamoto, M, Ishihara, A, et al. The regulation of bone metabolism and disorders by Wnt signaling. Int J Mol Sci. (2019) 20:5525. doi: 10.3390/ijms20225525
22. Song, S, Guo, Y, Yang, Y, and Fu, D. Advances in pathogenesis and therapeutic strategies for osteoporosis. Pharmacol Ther. (2022) 237:108168. doi: 10.1016/j.pharmthera.2022.108168
23. Liang, B, Burley, G, Lin, S, and Shi, YC. Osteoporosis pathogenesis and treatment: existing and emerging avenues. Cell Mol Biol Lett. (2022) 27:72. doi: 10.1186/s11658-022-00371-3
24. Yang, J, Andre, P, Ye, L, and Yang, YZ. The hedgehog signalling pathway in bone formation. Int J Oral Sci. (2015) 7:73–9. doi: 10.1038/ijos.2015.14
25. Bordukalo-Nikšić, T, Kufner, V, and Vukičević, S. The role of BMPs in the regulation of osteoclasts resorption and bone remodeling: from experimental models to clinical applications. Front Immunol. (2022) 13:869422. doi: 10.3389/fimmu.2022.869422
26. Zou, ML, Chen, ZH, Teng, YY, Liu, SY, Jia, Y, Zhang, KW, et al. The Smad dependent TGF-β and BMP signaling pathway in bone remodeling and therapies. Front Mol Biosci. (2021) 8:593310. doi: 10.3389/fmolb.2021.593310
27. Ikebuchi, Y, Aoki, S, Honma, M, Hayashi, M, Sugamori, Y, Khan, M, et al. Coupling of bone resorption and formation by RANKL reverse signalling. Nature. (2018) 561:195–200. doi: 10.1038/s41586-018-0482-7
28. Yasuda, H. Discovery of the RANKL/RANK/OPG system. J Bone Miner Metab. (2021) 39:2–11. doi: 10.1007/s00774-020-01175-1
29. Boyce, BF, and Xing, L, Biology of RANK. RANKL, and osteoprotegerin. Arthritis Res Ther. (2007) 9:S1. doi: 10.1186/ar2165
30. Zanotti, S, and Canalis, E. Notch signaling and the skeleton. Endocr Rev. (2016) 37:223–53. doi: 10.1210/er.2016-1002
31. Filipowska, J, Tomaszewski, KA, Niedźwiedzki, Ł, Walocha, JA, and Niedźwiedzki, T. The role of vasculature in bone development, regeneration and proper systemic functioning. Angiogenesis. (2017) 20:291–302. doi: 10.1007/s10456-017-9541-1
32. Tomlinson, RE, and Silva, MJ. Skeletal blood flow in bone repair and maintenance. Bone Res. (2013) 1:311–22. doi: 10.4248/BR201304002
33. Yuan, H, Xiao, L, Min, W, Yuan, W, Lu, S, and Huang, G. Bu-Shen-Tong-Luo decoction prevents bone loss via inhibition of bone resorption and enhancement of angiogenesis in ovariectomy-induced osteoporosis of rats. J Ethnopharmacol. (2018) 220:228–38. doi: 10.1016/j.jep.2018.01.007
34. Damian, LO, Simon, SP, Filipescu, I, Bocsa, C, Botar-Jid, C, and Rednic, S. Capillaroscopic findings in a case of Hajdu-Cheney syndrome. Osteoporos Int. (2016) 27:1269–73. doi: 10.1007/s00198-015-3314-8
35. Zhao, Q, Shen, X, Zhang, W, Zhu, G, Qi, J, and Deng, L. Mice with increased angiogenesis and osteogenesis due to conditional activation of HIF pathway in osteoblasts are protected from ovariectomy induced bone loss. Bone. (2012) 50:763–70. doi: 10.1016/j.bone.2011.12.003
36. Bharadwaj, S, Naidu, AG, Betageri, GV, Prasadarao, NV, and Naidu, AS. Milk ribonuclease-enriched lactoferrin induces positive effects on bone turnover markers in postmenopausal women. Osteoporos Int. (2009) 20:1603–11. doi: 10.1007/s00198-009-0839-8
37. Kusumbe, AP, Ramasamy, SK, and Adams, RH. Coupling of angiogenesis and osteogenesis by a specific vessel subtype in bone. Nature. (2014) 507:323–8. doi: 10.1038/nature13145
38. Lin, X, Xu, F, Zhang, KW, Qiu, WX, Zhang, H, Hao, Q, et al. Acacetin prevents bone loss by disrupting osteoclast formation and promoting type H vessel formation in Ovariectomy-induced osteoporosis. Front Cell Dev Biol. (2022) 10:796227. doi: 10.3389/fcell.2022.796227
39. Wang, L, Zhou, F, Zhang, P, Wang, H, Qu, Z, Jia, P, et al. Human type H vessels are a sensitive biomarker of bone mass. Cell Death Dis. (2017) 8:e2760. doi: 10.1038/cddis.2017.36
40. Xie, H, Cui, Z, Wang, L, Xia, Z, Hu, Y, Xian, L, et al. PDGF-BB secreted by preosteoclasts induces angiogenesis during coupling with osteogenesis. Nat Med. (2014) 20:1270–8. doi: 10.1038/nm.3668
41. Ramasamy, SK, Kusumbe, AP, Wang, L, and Adams, RH. Endothelial notch activity promotes angiogenesis and osteogenesis in bone. Nature. (2014) 507:376–80. doi: 10.1038/nature13146
42. Fayed, HA, Barakat, BM, Elshaer, SS, Abdel-Naim, AB, and Menze, ET. Antiosteoporotic activities of isoquercitrin in ovariectomized rats: role of inhibiting hypoxia inducible factor-1 alpha. Eur J Pharmacol. (2019) 865:172785. doi: 10.1016/j.ejphar.2019.172785
43. Pandit, AP, Omase, SB, and Mute, VM. A chitosan film containing quercetin-loaded transfersomes for treatment of secondary osteoporosis. Drug Deliv Transl Res. (2020) 10:1495–506. doi: 10.1007/s13346-020-00708-5
44. Abd El-Fattah, AI, Fathy, MM, Ali, ZY, El-Garawany, AEA, and Mohamed, EK. Enhanced therapeutic benefit of quercetin-loaded phytosome nanoparticles in ovariectomized rats. Chem Biol Interact. (2017) 271:30–8. doi: 10.1016/j.cbi.2017.04.026
45. Chauhan, S, Sharma, A, Upadhyay, NK, Singh, G, Lal, UR, and Goyal, R. In-vitro osteoblast proliferation and in-vivo anti-osteoporotic activity of Bombax ceiba with quantification of Lupeol, gallic acid and β-sitosterol by HPTLC and HPLC. BMC Complement Altern Med. (2018) 18:233. doi: 10.1186/s12906-018-2299-1
46. Vakili, S, Zal, F, Mostafavi-Pour, Z, Savardashtaki, A, and Koohpeyma, F. Quercetin and vitamin E alleviate ovariectomy-induced osteoporosis by modulating autophagy and apoptosis in rat bone cells. J Cell Physiol. (2021) 236:3495–509. doi: 10.1002/jcp.30087
47. De Maré, A, Opdebeeck, B, Neven, E, D'Haese, PC, and Verhulst, A. Sclerostin protects against vascular calcification development in mice. J Bone Miner Res. (2022) 37:687–99. doi: 10.1002/jbmr.4503
48. Mandatori, D, Pelusi, L, Schiavone, V, Pipino, C, Di Pietro, N, and Pandolfi, A. The dual role of vitamin K2 in "bone-vascular crosstalk": opposite effects on bone loss and vascular calcification. Nutrients. (2021) 13:222. doi: 10.3390/nu13041222
49. Toni, R, Di Conza, G, Barbaro, F, Zini, N, Consolini, E, Dallatana, D, et al. Microtopography of immune cells in osteoporosis and bone lesions by endocrine disruptors. Front Immunol. (2020) 11:1737. doi: 10.3389/fimmu.2020.01737
50. Liang, W, Luo, Z, Ge, S, Li, M, Du, J, Yang, M, et al. Oral administration of quercetin inhibits bone loss in rat model of diabetic osteopenia. Eur J Pharmacol. (2011) 670:317–24. doi: 10.1016/j.ejphar.2011.08.014
51. Shi, T, Liu, T, Kou, Y, Rong, X, Meng, L, Cui, Y, et al. The synergistic effect of Zuogui pill and Eldecalcitol on improving bone mass and osteogenesis in type 2 diabetic osteoporosis. Medicina. (2023) 59:1414. doi: 10.3390/medicina59081414
52. Fischer, V, and Haffner-Luntzer, M. Interaction between bone and immune cells: implications for postmenopausal osteoporosis. Semin Cell Dev Biol. (2022) 123:14–21. doi: 10.1016/j.semcdb.2021.05.014
53. Saxena, Y, Routh, S, and Mukhopadhaya, A. Immunoporosis: role of innate immune cells in osteoporosis. Front Immunol. (2021) 12:687037. doi: 10.3389/fimmu.2021.687037
54. Srivastava, RK, Dar, HY, and Mishra, PK. Immunoporosis: immunology of osteoporosis-role of T cells. Front Immunol. (2018) 9:657. doi: 10.3389/fimmu.2018.00657
55. Weitzmann, MN. Bone and the immune system. Toxicol Pathol. (2017) 45:911–24. doi: 10.1177/0192623317735316
56. Onoe, Y, Miyaura, C, Kaminakayashiki, T, Nagai, Y, Noguchi, K, Chen, QR, et al. IL-13 and IL-4 inhibit bone resorption by suppressing cyclooxygenase-2-dependent prostaglandin synthesis in osteoblasts. J Immunol. (1996) 156:758–64. doi: 10.4049/jimmunol.156.2.758
57. Balani, D, Aeberli, D, Hofstetter, W, and Seitz, M. Interleukin-17A stimulates granulocyte-macrophage colony-stimulating factor release by murine osteoblasts in the presence of 1,25-dihydroxyvitamin D(3) and inhibits murine osteoclast development in vitro. Arthritis Rheum. (2013) 65:436–46. doi: 10.1002/art.37762
58. Li, JY, Yu, M, Tyagi, AM, Vaccaro, C, Hsu, E, Adams, J, et al. IL-17 receptor signaling in osteoblasts/osteocytes mediates PTH-induced bone loss and enhances Osteocytic RANKL production. J Bone Miner Res. (2019) 34:349–60. doi: 10.1002/jbmr.3600
59. Tan, J, Dai, A, Pan, L, Zhang, L, Wang, Z, Ke, T, et al. Inflamm-aging-related cytokines of IL-17 and IFN-γ accelerate Osteoclastogenesis and periodontal destruction. J Immunol Res. (2021) 2021:1–12. doi: 10.1155/2021/9919024
60. Lam, J, Takeshita, S, Barker, JE, Kanagawa, O, Ross, FP, and Teitelbaum, SL. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest. (2000) 106:1481–8. doi: 10.1172/JCI11176
61. Croes, M, Öner, FC, van Neerven, D, Sabir, E, Kruyt, MC, Blokhuis, TJ, et al. Proinflammatory T cells and IL-17 stimulate osteoblast differentiation. Bone. (2016) 84:262–70. doi: 10.1016/j.bone.2016.01.010
62. Kotake, S, Udagawa, N, Takahashi, N, Matsuzaki, K, Itoh, K, Ishiyama, S, et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest. (1999) 103:1345–52. doi: 10.1172/JCI5703
63. Wang, Z, Tan, J, Lei, L, Sun, W, Wu, Y, Ding, P, et al. The positive effects of secreting cytokines IL-17 and IFN-γ on the early-stage differentiation and negative effects on the calcification of primary osteoblasts in vitro. Int Immunopharmacol. (2018) 57:1–10. doi: 10.1016/j.intimp.2018.02.002
64. Du, D, Zhou, Z, Zhu, L, Hu, X, Lu, J, Shi, C, et al. TNF-α suppresses osteogenic differentiation of MSCs by accelerating P2Y(2) receptor in estrogen-deficiency induced osteoporosis. Bone. (2018) 117:161–70. doi: 10.1016/j.bone.2018.09.012
65. Sun, W, Meednu, N, Rosenberg, A, Rangel-Moreno, J, Wang, V, Glanzman, J, et al. B cells inhibit bone formation in rheumatoid arthritis by suppressing osteoblast differentiation. Nat Commun. (2018) 9:5127. doi: 10.1038/s41467-018-07626-8
66. Valenzona, HO, Pointer, R, Ceredig, R, and Osmond, DG. Prelymphomatous B cell hyperplasia in the bone marrow of interleukin-7 transgenic mice: precursor B cell dynamics, microenvironmental organization and osteolysis. Exp Hematol. (1996) 24:1521–9.
67. Dougall, WC, Glaccum, M, Charrier, K, Rohrbach, K, Brasel, K, De Smedt, T, et al. RANK is essential for osteoclast and lymph node development. Genes Dev. (1999) 13:2412–24. doi: 10.1101/gad.13.18.2412
68. Crowther, JS, Drasar, BS, Goddard, P, Hill, MJ, and Johnson, K. The effect of a chemically defined diet on the faecal flora and faecal steroid concentration. Gut. (1973) 14:790–3. doi: 10.1136/gut.14.10.790
69. Zhang, Z, Yuan, W, Deng, J, Wang, D, Zhang, T, Peng, L, et al. Granulocyte colony stimulating factor (G-CSF) regulates neutrophils infiltration and periodontal tissue destruction in an experimental periodontitis. Mol Immunol. (2020) 117:110–21. doi: 10.1016/j.molimm.2019.11.003
70. Makiishi-Shimobayashi, C, Tsujimura, T, Iwasaki, T, Yamada, N, Sugihara, A, Okamura, H, et al. Interleukin-18 up-regulates osteoprotegerin expression in stromal/osteoblastic cells. Biochem Biophys Res Commun. (2001) 281:361–6. doi: 10.1006/bbrc.2001.4380
71. Michalski, MN, and McCauley, LK. Macrophages and skeletal health. Pharmacol Ther. (2017) 174:43–54. doi: 10.1016/j.pharmthera.2017.02.017
72. Lassus, J, Salo, J, Jiranek, WA, Santavirta, S, Nevalainen, J, Matucci-Cerinic, M, et al. Macrophage activation results in bone resorption. Clin Orthop Relat Res. (1998) 352:715. doi: 10.1097/00003086-199807000-00003
73. Murray, PJ. Macrophage polarization. Annu Rev Physiol. (2017) 79:541–66. doi: 10.1146/annurev-physiol-022516-034339
74. Ponzetti, M, and Rucci, N. Updates on Osteoimmunology: What's new on the cross-talk between bone and immune system. Front Endocrinol. (2019) 10:236. doi: 10.3389/fendo.2019.00236
75. Huang, R, Wang, X, Zhou, Y, and Xiao, Y. RANKL-induced M1 macrophages are involved in bone formation. Bone Res. (2017) 5:17019. doi: 10.1038/boneres.2017.19
76. Loi, F, Córdova, LA, Zhang, R, Pajarinen, J, Lin, TH, Goodman, SB, et al. The effects of immunomodulation by macrophage subsets on osteogenesis in vitro. Stem Cell Res Ther. (2016) 7:15. doi: 10.1186/s13287-016-0276-5
77. Liu, S, Chen, T, Wang, R, Huang, H, Fu, S, Zhao, Y, et al. Exploring the effect of the "quaternary regulation" theory of "peripheral nerve-angiogenesis-osteoclast-osteogenesis" on osteoporosis based on neuropeptides. Front Endocrinol. (2022) 13:908043. doi: 10.3389/fendo.2022.908043
78. Baldock, PA, Lee, NJ, Driessler, F, Lin, S, Allison, S, Stehrer, B, et al. Neuropeptide Y knockout mice reveal a central role of NPY in the coordination of bone mass to body weight. PLoS One. (2009) 4:e8415. doi: 10.1371/journal.pone.0008415
79. Herring, N, Tapoulal, N, Kalla, M, Ye, X, Borysova, L, Lee, R, et al. Neuropeptide-Y causes coronary microvascular constriction and is associated with reduced ejection fraction following ST-elevation myocardial infarction. Eur Heart J. (2019) 40:1920–9. doi: 10.1093/eurheartj/ehz115
80. Igwe, JC, Jiang, X, Paic, F, Ma, L, Adams, DJ, Baldock, PA, et al. Neuropeptide Y is expressed by osteocytes and can inhibit osteoblastic activity. J Cell Biochem. (2009) 108:621–30. doi: 10.1002/jcb.22294
81. Lee, NJ, Doyle, KL, Sainsbury, A, Enriquez, RF, Hort, YJ, Riepler, SJ, et al. Critical role for Y1 receptors in mesenchymal progenitor cell differentiation and osteoblast activity. J Bone Miner Res. (2010) 25:1736–47. doi: 10.1002/jbmr.61
82. Abdurahman, A, Li, X, Li, J, Liu, D, Zhai, L, Wang, X, et al. Loading-driven PI3K/Akt signaling and erythropoiesis enhanced angiogenesis and osteogenesis in a postmenopausal osteoporosis mouse model. Bone. (2022) 157:116346. doi: 10.1016/j.bone.2022.116346
83. Khosla, S, Oursler, MJ, and Monroe, DG. Estrogen and the skeleton. Trends Endocrinol Metab. (2012) 23:576–81. doi: 10.1016/j.tem.2012.03.008
84. Li, L, Chen, B, Zhu, R, Li, R, Tian, Y, Liu, C, et al. Fructus Ligustri Lucidi preserves bone quality through the regulation of gut microbiota diversity, oxidative stress, TMAO and Sirt6 levels in aging mice. Aging (Albany NY). (2019) 11:9348–68. doi: 10.18632/aging.102376
85. Callaway, DA, and Jiang, JX. Reactive oxygen species and oxidative stress in osteoclastogenesis, skeletal aging and bone diseases. J Bone Miner Metab. (2015) 33:359–70. doi: 10.1007/s00774-015-0656-4
86. Wang, L, Ma, R, Guo, Y, Sun, J, Liu, H, Zhu, R, et al. Antioxidant effect of Fructus Ligustri Lucidi aqueous extract in Ovariectomized rats is mediated through Nox4-ROS-NF-κB pathway. Front Pharmacol. (2017) 8:266. doi: 10.3389/fphar.2017.00266
87. Bian, W, Xiao, S, Yang, L, Chen, J, and Deng, S. Quercetin promotes bone marrow mesenchymal stem cell proliferation and osteogenic differentiation through the H19/miR-625-5p axis to activate the Wnt/β-catenin pathway. BMC Complement Med Ther. (2021) 21:243. doi: 10.1186/s12906-021-03418-8
88. Li, Y, Wang, J, Chen, G, Feng, S, Wang, P, Zhu, X, et al. Quercetin promotes the osteogenic differentiation of rat mesenchymal stem cells via mitogen-activated protein kinase signaling. Exp Ther Med. (2015) 9:2072–80. doi: 10.3892/etm.2015.2388
89. Oh, JH, Karadeniz, F, Seo, Y, and Kong, CS. Effect of quercetin 3-O-β-D-Galactopyranoside on the Adipogenic and Osteoblastogenic differentiation of human bone marrow-derived mesenchymal stromal cells. Int J Mol Sci. (2020) 21:44. doi: 10.3390/ijms21218044
90. Pang, XG, Cong, Y, Bao, NR, Li, YG, and Zhao, JN. Quercetin stimulates bone marrow mesenchymal stem cell differentiation through an estrogen receptor-mediated pathway. Biomed Res Int. (2018) 2018:1–11. doi: 10.1155/2018/4178021
91. Wang, N, Wang, L, Yang, J, Wang, Z, and Cheng, L. Quercetin promotes osteogenic differentiation and antioxidant responses of mouse bone mesenchymal stem cells through activation of the AMPK/SIRT1 signaling pathway. Phytother Res. (2021) 35:2639–50. doi: 10.1002/ptr.7010
92. Yuan, Z, Min, J, Zhao, Y, Cheng, Q, Wang, K, Lin, S, et al. Quercetin rescued TNF-alpha-induced impairments in bone marrow-derived mesenchymal stem cell osteogenesis and improved osteoporosis in rats. Am J Transl Res. (2018) 10:4313–21.
93. Gan, L, Leng, Y, Min, J, Luo, XM, Wang, F, and Zhao, J. Kaempferol promotes the osteogenesis in rBMSCs via mediation of SOX2/miR-124-3p/PI3K/Akt/mTOR axis. Eur J Pharmacol. (2022) 927:174954. doi: 10.1016/j.ejphar.2022.174954
94. Zhu, J, Tang, H, Zhang, Z, Zhang, Y, Qiu, C, Zhang, L, et al. Kaempferol slows intervertebral disc degeneration by modifying LPS-induced osteogenesis/adipogenesis imbalance and inflammation response in BMSCs. Int Immunopharmacol. (2017) 43:236–42. doi: 10.1016/j.intimp.2016.12.020
95. Byun, MR, Jeong, H, Bae, SJ, Kim, AR, Hwang, ES, and Hong, JH. TAZ is required for the osteogenic and anti-adipogenic activities of kaempferol. Bone. (2012) 50:364–72. doi: 10.1016/j.bone.2011.10.035
96. Ding, Y, Jiang, H, Meng, B, Zhu, B, Yu, X, and Xiang, G. Sweroside-mediated mTORC1 hyperactivation in bone marrow mesenchymal stem cells promotes osteogenic differentiation. J Cell Biochem. (2019) 120:16025–36. doi: 10.1002/jcb.28882
97. Wu, QC, Tang, XY, Dai, ZQ, Dai, Y, Xiao, HH, and Yao, XS. Sweroside promotes osteoblastic differentiation and mineralization via interaction of membrane estrogen receptor-α and GPR30 mediated p38 signalling pathway on MC3T3-E1 cells. Phytomedicine. (2020) 68:153146. doi: 10.1016/j.phymed.2019.153146
98. Choi, Y, Kim, MH, and Yang, WM. Promotion of osteogenesis by Sweroside via BMP2-involved signaling in postmenopausal osteoporosis. Phytother Res. (2021) 35:7050–63. doi: 10.1002/ptr.7336
99. Hu, N, Ren, S, Li, W, Zhang, T, and Zhao, C. Morroniside promotes bone marrow mesenchymal stem cell proliferation in rats. Mol Med Rep. (2013) 7:1565–70. doi: 10.3892/mmr.2013.1399
100. Sun, Y, Zhu, Y, Liu, X, Chai, Y, and Xu, J. Morroniside attenuates high glucose-induced BMSC dysfunction by regulating the Glo1/AGE/RAGE axis. Cell Prolif. (2020) 53:e12866. doi: 10.1111/cpr.12866
101. Dong, R, Jia, Y, Yang, H, Luo, G, Li, Y, and Sun, T. Effects and mechanism of morroniside on osteogenic differentiation and proliferation of mouse MC3T3-E1 cells. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. (2022) 36:889–95. doi: 10.7507/1002-1892.202202088
102. Yang, HZ, Dong, R, Jia, Y, Li, Y, Luo, G, Li, T, et al. Morroniside ameliorates glucocorticoid-induced osteoporosis and promotes osteoblastogenesis by interacting with sodium-glucose cotransporter 2. Pharm Biol. (2023) 61:416–26. doi: 10.1080/13880209.2023.2173787
103. Li, X, Zhu, Y, Lin, X, Chen, C, Liu, H, and Shi, Y. Beclin1-and Atg13-dependent autophagy activation and morroniside have synergistic effect on osteoblastogenesis. Exp Biol Med (Maywood). (2022) 247:1764–75. doi: 10.1177/15353702221116879
104. Liu, H, Li, X, Lin, J, and Lin, M. Morroniside promotes the osteogenesis by activating PI3K/Akt/mTOR signaling. Biosci Biotechnol Biochem. (2021) 85:332–9. doi: 10.1093/bbb/zbaa010
105. Gao, F, Xia, SL, Wang, XH, Zhou, XX, and Wang, J. Cornuside I promoted osteogenic differentiation of bone mesenchymal stem cells through PI3K/Akt signaling pathway. J Orthop Surg Res. (2021) 16:397. doi: 10.1186/s13018-021-02508-0
106. Wang, H, Yan, Y, Lan, H, Wei, N, Zheng, Z, Wu, L, et al. Notoginsenoside R1 promotes migration, Adhesin, spreading, and osteogenic differentiation of human adipose tissue-derived mesenchymal stromal cells. Molecules. (2022) 27:3403. doi: 10.3390/molecules27113403
107. Kim, JM, Lin, C, Stavre, Z, Greenblatt, MB, and Shim, JH. Osteoblast-osteoclast communication and bone homeostasis. Cells. (2020) 9:73. doi: 10.3390/cells9092073
108. Guo, C, Hou, GQ, Li, XD, Xia, X, Liu, DX, Huang, DY, et al. Quercetin triggers apoptosis of lipopolysaccharide (LPS)-induced osteoclasts and inhibits bone resorption in RAW264.7 cells. Cell Physiol Biochem. (2012) 30:123–36. doi: 10.1159/000339052
109. Kim, HR, Kim, BM, Won, JY, Lee, KA, Ko, HM, Kang, YS, et al. Quercetin, a plant polyphenol, has potential for the prevention of bone destruction in rheumatoid arthritis. J Med Food. (2019) 22:152–61. doi: 10.1089/jmf.2018.4259
110. Woo, JT, Nakagawa, H, Notoya, M, Yonezawa, T, Udagawa, N, Lee, IS, et al. Quercetin suppresses bone resorption by inhibiting the differentiation and activation of osteoclasts. Biol Pharm Bull. (2004) 27:504–9. doi: 10.1248/bpb.27.504
111. Nowak, B, Matuszewska, A, Nikodem, A, Filipiak, J, Landwójtowicz, M, Sadanowicz, E, et al. Oral administration of kaempferol inhibits bone loss in rat model of ovariectomy-induced osteopenia. Pharmacol Rep. (2017) 69:1113–9. doi: 10.1016/j.pharep.2017.05.002
112. Pang, JL, Ricupero, DA, Huang, S, Fatma, N, Singh, DP, Romero, JR, et al. Differential activity of kaempferol and quercetin in attenuating tumor necrosis factor receptor family signaling in bone cells. Biochem Pharmacol. (2006) 71:818–26. doi: 10.1016/j.bcp.2005.12.023
113. Wong, SK, Chin, KY, and Ima-Nirwana, S. The Osteoprotective effects of Kaempferol: the evidence from in vivo and in vitro studies. Drug Des Devel Ther. (2019) 13:3497–514. doi: 10.2147/DDDT.S227738
114. Lee, CG, Kim, DW, Kim, J, Uprety, LP, Oh, KI, Singh, S, et al. Effects of Loganin on bone formation and resorption in vitro and in vivo. Int J Mol Sci. (2022) 23:4128. doi: 10.3390/ijms232214128
115. Park, E, Lee, CG, Lim, E, Hwang, S, Yun, SH, Kim, J, et al. Osteoprotective effects of Loganic acid on osteoblastic and osteoclastic cells and osteoporosis-induced mice. Int J Mol Sci. (2020) 22:233. doi: 10.3390/ijms22010233
116. Lee, CG, Kim, J, Yun, SH, Hwang, S, Jeon, H, Park, E, et al. Anti-osteoporotic effect of Morroniside on osteoblast and osteoclast differentiation in vitro and Ovariectomized mice in vivo. Int J Mol Sci. (2021) 22:642. doi: 10.3390/ijms221910642
117. Zhao, S, Yan, L, Li, X, Zhang, Z, Sun, Y, and Wang, J. Notoginsenoside R1 suppresses wear particle-induced osteolysis and RANKL mediated osteoclastogenesis in vivo and in vitro. Int Immunopharmacol. (2017) 47:118–25. doi: 10.1016/j.intimp.2017.03.018
118. Zhang, P, Ye, J, Dai, J, Wang, Y, Chen, G, Hu, J, et al. Gallic acid inhibits osteoclastogenesis and prevents ovariectomy-induced bone loss. Front Endocrinol. (2022) 13:963237. doi: 10.3389/fendo.2022.963237
119. Kim, JY, Kim, YK, Choi, MK, Oh, J, Kwak, HB, and Kim, JJ. Effect of Cornus Officinalis on receptor activator of nuclear factor-kappaB ligand (RANKL)-induced osteoclast differentiation. J Bone Metab. (2012) 19:121–7. doi: 10.11005/jbm.2012.19.2.121
120. Liu, T, Sun, F, Cui, J, Zheng, S, Li, Z, Guo, D, et al. Morroniside enhances angiogenesis and improves cardiac function following acute myocardial infarction in rats. Eur J Pharmacol. (2020) 872:172954. doi: 10.1016/j.ejphar.2020.172954
121. Liu, T, Xiang, B, Guo, D, Sun, F, Wei, R, Zhang, G, et al. Morroniside promotes angiogenesis and further improves microvascular circulation after focal cerebral ischemia/reperfusion. Brain Res Bull. (2016) 127:111–8. doi: 10.1016/j.brainresbull.2016.09.004
122. Sun, FL, Wang, W, Cheng, H, Wang, Y, Li, L, Xue, JL, et al. Morroniside improves microvascular functional integrity of the neurovascular unit after cerebral ischemia. PLoS One. (2014) 9:e101194. doi: 10.1371/journal.pone.0101194
123. Choi, YH, Jin, GY, Li, GZ, and Yan, GH. Cornuside suppresses lipopolysaccharide-induced inflammatory mediators by inhibiting nuclear factor-kappa B activation in RAW 264.7 macrophages. Biol Pharm Bull. (2011) 34:959–66. doi: 10.1248/bpb.34.959
124. Park, C, Lee, H, Kwon, CY, Kim, GY, Jeong, JW, Kim, SO, et al. Loganin inhibits lipopolysaccharide-induced inflammation and oxidative response through the activation of the Nrf2/HO-1 signaling pathway in RAW264.7 macrophages. Biol Pharm Bull. (2021) 44:875–83. doi: 10.1248/bpb.b21-00176
125. Wang, R, Dong, Z, Lan, X, Liao, Z, and Chen, M. Sweroside alleviated LPS-induced inflammation via SIRT1 mediating NF-κB and FOXO1 signaling pathways in RAW264.7 cells. Molecules. (2019) 24:872. doi: 10.3390/molecules24050872
126. Zhang, JH, Di, Y, Wu, LY, He, YL, Zhao, T, Huang, X, et al. 5-HMF prevents against oxidative injury via APE/Ref-1. Free Radic Res. (2015) 49:86–94. doi: 10.3109/10715762.2014.981260
127. Tsai, CF, Chen, GW, Chen, YC, Shen, CK, Lu, DY, Yang, LY, et al. Regulatory effects of quercetin on M1/M2 macrophage polarization and oxidative/Antioxidative balance. Nutrients. (2021) 14:67. doi: 10.3390/nu14010067
128. Liu, S, Shen, H, Li, J, Gong, Y, Bao, H, Zhang, J, et al. Loganin inhibits macrophage M1 polarization and modulates sirt1/NF-κB signaling pathway to attenuate ulcerative colitis. Bioengineered. (2020) 11:628–39. doi: 10.1080/21655979.2020.1774992
129. Park, C, Cha, HJ, Lee, H, Kim, GY, and Choi, YH. The regulation of the TLR4/NF-κB and Nrf2/HO-1 signaling pathways is involved in the inhibition of lipopolysaccharide-induced inflammation and oxidative reactions by morroniside in RAW 264.7 macrophages. Arch Biochem Biophys. (2021) 706:108926. doi: 10.1016/j.abb.2021.108926
130. Wang, Q, Ying, L, Wei, B, Ji, Y, and Xu, Y. Effects of quercetin on apoptosis and extracellular matrix degradation of chondrocytes induced by oxidative stress-mediated pyroptosis. J Biochem Mol Toxicol. (2022) 36:e22951. doi: 10.1002/jbt.22951
131. Guo, AJ, Choi, RC, Zheng, KY, Chen, VP, Dong, TT, Wang, ZT, et al. Kaempferol as a flavonoid induces osteoblastic differentiation via estrogen receptor signaling. Chin Med. (2012) 7:10. doi: 10.1186/1749-8546-7-10
132. Li, X, Lin, H, Zhang, X, Jaspers, RT, Yu, Q, Ji, Y, et al. Notoginsenoside R1 attenuates oxidative stress-induced osteoblast dysfunction through JNK signalling pathway. J Cell Mol Med. (2021) 25:11278–89. doi: 10.1111/jcmm.17054
133. Wang, T, Wan, D, Shao, L, Dai, J, and Jiang, C. Notoginsenoside R1 stimulates osteogenic function in primary osteoblasts via estrogen receptor signaling. Biochem Biophys Res Commun. (2015) 466:232–9. doi: 10.1016/j.bbrc.2015.09.014
134. Xia, B, Xu, B, Sun, Y, Xiao, L, Pan, J, Jin, H, et al. The effects of Liuwei Dihuang on canonical Wnt/β-catenin signaling pathway in osteoporosis. J Ethnopharmacol. (2014) 153:133–41. doi: 10.1016/j.jep.2014.01.040
135. Liu, MM, Dong, R, Hua, Z, Lv, NN, Ma, Y, Huang, GC, et al. Therapeutic potential of Liuwei Dihuang pill against KDM7A and Wnt/β-catenin signaling pathway in diabetic nephropathy-related osteoporosis. Biosci Rep. (2020) 40:778. doi: 10.1042/BSR20201778
136. Lai, N, Zhang, Z, Wang, B, Miao, X, Guo, Y, Yao, C, et al. Regulatory effect of traditional Chinese medicinal formula Zuo-Gui-Wan on the Th17/Treg paradigm in mice with bone loss induced by estrogen deficiency. J Ethnopharmacol. (2015) 166:228–39. doi: 10.1016/j.jep.2015.03.011
137. Liu, F, Tan, F, Tong, W, Fan, Q, Ye, S, Lu, S, et al. Effect of Zuoguiwan on osteoporosis in ovariectomized rats through RANKL/OPG pathway mediated by β2AR. Biomed Pharmacother. (2018) 103:1052–60. doi: 10.1016/j.biopha.2018.04.102
138. Shen, G, Shang, Q, Zhang, Z, Zhao, W, Chen, H, Mijiti, I, et al. Zuo-Gui-Wan aqueous extract ameliorates glucocorticoid-induced spinal osteoporosis of rats by regulating let-7f and autophagy. Front Endocrinol. (2022) 13:878963. doi: 10.3389/fendo.2022.878963
139. Komori, T. Animal models for osteoporosis. Eur J Pharmacol. (2015) 759:287–94. doi: 10.1016/j.ejphar.2015.03.028
Keywords: osteoporosis, Cornus officinalis, kidney-tonifying herbs, bone homeostasis, effective ingredients, pharmacological mechanisms
Citation: Tang X, Huang Y, Fang X, Tong X, Yu Q, Zheng W and Fu F (2023) Cornus officinalis: a potential herb for treatment of osteoporosis. Front. Med. 10:1289144. doi: 10.3389/fmed.2023.1289144
Edited by:
Lingfeng Zeng, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, ChinaReviewed by:
IGP Suka Aryana, Udayana University, IndonesiaZiwei Zhang, Northeast Agricultural University, China
Copyright © 2023 Tang, Huang, Fang, Tong, Yu, Zheng and Fu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Wenbiao Zheng, endic3BpbmVAMTYzLmNvbQ==; Fangda Fu, MjAyMDkxMDFAemNtdS5lZHUuY24=
†These authors have contributed equally to this work